BioImage currently licenses its patented technologies in two key areas: the well-established Redistribution^® protein translocation assay technology, and a growing family of patented technologies for protein-protein interaction assays.

For further information on licensing, contact us at:
Len Pagliaro
E-mail:
Tel: +45 3954 0825

download patent portfolio overview

• The Redistribution^® patent family describes our approach to drug discovery based on high throughput screening using quantitation of intracellular protein translocations.
1. A method for extracting quantitative information relating to an influence on a cellular response: WO 98/45704, EP 0986753B1, US 6,518,021.
• The protein-protein interaction patent family describes our tools for assaying protein-protein interactions in mammalian cells in high throughput.
1. Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins¹:WO 01/87919, US 6,780,599.
2. Two green fluorescent protein fragments and their use in a method for detecting protein-protein interactions: WO 03/089464.
3. Translocation dependent complementation for drug screening: WO 03/089627.
4. A method for detecting intracellular protein-protein interactions using three heterologous conjugates: WO 03/029827.

Notes:
1. Fisher BioImage ApS has obtained exclusive world-wide license from Yale University.
The trademarks BioImage and Redistribution^® used herein are owned by Fisher BioImage ApS, Denmark; BioImage is part of Thermo Fisher Scientific.